Randall Kaye News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Partnership Explores the Role of Sleep in Neurological Disorders

Partnership Explores the Role of Sleep in Neurological Disorders
sleepreviewmag.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sleepreviewmag.com Daily Mail and Mail on Sunday newspapers.

Randall kayeJacob donoghueLongboard pharmaceuticals incLongboard pharmaceuticalsBeacon biosignalsBeacon platform

Longboard Pharmaceuticals to Present Late-Breaking Data from the PACIFIC Study at the American Academy of Neurology (AAN) Annual Meeting on April 15

PACIFIC Study Phase 1b/2a clinical data to be featured in a podium presentation at an Emerging Science Session at the AAN Annual Meeting Data will be featured in an encore presentation at the.

United statesRandall kayeEncephalopathies deesLongboard pharmaceuticals incExchange commissionLongboard pharmaceuticalsChief medical officerEpileptic encephalopathiesAdult patientsEmerging science sessionScientific platform sessionPresentation numberSeventeenth eilat conferenceNew antiepileptic drugsPrivate securities litigation reform act

Forget the Magnificent Seven -- This Stock Has Nearly Quadrupled in 2024, and Wall Street Thinks It Can Go a Lot Higher

You might say that this biotech stock is magnificent.

Randall kayeTracy dixon salazarKevinr lindLongboard pharmaceuticalsMeta platformsMagnificent sevenWall streetLongboard pharmaceuticalLennox gastaut syndromeMotley fool stock advisorStock advisorMagnificent sevenWall streetClinical studySeizure frequency

Positive data reported from phase 1b/2a study of oral superagonist for epileptic seizures

Positive data reported from phase 1b/2a study of oral superagonist for epileptic seizures
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

Shenaz baghaRandall kayeLongboard pharmaceuticals

Longboard Pharmaceuticals Announces Positive Topline Data from the PACIFIC Study, a Phase 1b/2a Clinical Trial, for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (DEEs)

Bexicaserin achieved a median seizure reduction of 53.3% in countable motor seizures compared to 20.8% in the placebo group across the DEE study population A median seizure reduction of 72.1% in.

United statesRandall kayeEncephalopathies deesTracy dixon salazarKevinr lindDennis dlugosEpilepsy study consortiumLongboard pharmaceuticals incExchange commissionLongboard pharmaceuticalsEpileptic encephalopathiesTopline resultsEfficacy dataSafety dataChief medicalExecutive director